Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
2022 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
2021 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
Sales 2019 | - | Sales 2020 | - | Capitalization | 551K 45.84M |
---|---|---|---|---|---|
Net income 2019 | - 0 | Net income 2020 | - 0 | EV / Sales 2019 | - |
Net Debt 2019 | 1.12M 93.32M | Net Debt 2020 | 874K 72.8M | EV / Sales 2020 | - |
P/E ratio 2019 |
3.09
x | P/E ratio 2020 |
-1.77
x | Employees | 3 |
Yield 2019 * |
-
| Yield 2020 |
-
| Free-Float | 93.84% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 70 | 22/03/22 | |
James Grainer
CHM | Chairman | 69 | 22/20/22 |
Lois Chandler
COO | Chief Operating Officer | - | 01/10/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 22/03/22 | |
James Grainer
CHM | Chairman | 69 | 22/20/22 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 71 | 22/20/22 |
1st Jan change | Capi. | |
---|---|---|
0.00% | 64 | |
+44.48% | 55.07B | |
+43.57% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- CRXM Stock